Do you ever use molecular assays such as Oncotype to modify your recommendations for withholding RT after lumpectomy in invasive breast cancer?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on
This is part of the ongoing IDEA study. At present, we don't use Oncotype DX information for withholding RT for invasive breast cancer after lumpectomy.
Join for free or sign in to see the full answer